Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

35.5K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.5K
Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The Ras Gene02:38

The Ras Gene

6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal atlas of human atherosclerosis links granular vascular cell states to coronary artery disease risk.

medRxiv : the preprint server for health sciences·2026
Same author

Increased expression of a subset of genes within reduced copy number regions across multiple cancer types.

bioRxiv : the preprint server for biology·2026
Same author

A simple method for analyzing competitive growth of multiple cell types in xenograft tumors.

bioRxiv : the preprint server for biology·2026
Same author

Clinical characteristics, management, and hematopoietic cell transplantation of patients with TLR8 gain-of-function.

Blood advances·2025
Same author

A Plasma-based Deep Proteomic Platform for early-stage Breast Cancer Detection.

Endocrinology·2025
Same author

Multicellular immune ecotypes within solid tumors predict real-world therapeutic benefits with immune checkpoint inhibitors.

Nature communications·2025

Related Experiment Video

Updated: Aug 2, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.2K

Induction of PARP7 Creates a Vulnerability for Growth Inhibition by RBN2397 in Prostate Cancer Cells.

Chunsong Yang1, Krzysztof Wierbiłowicz1,2, Natalia M Dworak3

  • 1Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, Virginia.

Cancer Research Communications
|April 20, 2023
PubMed
Summary

A new drug, RBN2397, effectively inhibits poly(ADP-ribose) polymerase 7 (PARP7) and reduces prostate cancer cell growth. This PARP7 inhibitor shows promise as a therapeutic target for advanced prostate cancer.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.0K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.1K

Related Experiment Videos

Last Updated: Aug 2, 2025

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.2K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.0K
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

4.1K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Poly(ADP-ribose) polymerase 7 (PARP7) is an enzyme that modifies protein function through ADP-ribosylation.
  • PARP7 influences gene expression in prostate cancer cells, partly via transcription factor modification.
  • Targeting PARP7 presents a potential strategy for prostate cancer treatment.

Purpose of the Study:

  • To investigate the effects of the PARP7 inhibitor RBN2397 on prostate cancer cells.
  • To assess RBN2397's impact on androgen receptor (AR)-positive and AR-negative prostate cancer models.
  • To explore the mechanism of action of RBN2397 in prostate cancer.

Main Methods:

  • Utilized RBN2397, a catalytic inhibitor of PARP7.
  • Studied RBN2397's effects on AR-positive and AR-negative prostate cancer cell lines.
  • Assessed AR ADP-ribosylation, cell growth inhibition, and PARP7 localization within the nucleus.

Main Results:

  • RBN2397 demonstrated nanomolar potency in inhibiting androgen-induced AR ADP-ribosylation.
  • RBN2397 inhibited the growth of prostate cancer cells stimulated by AR or aryl hydrocarbon receptor ligands.
  • RBN2397 treatment led to PARP7 trapping in a detergent-resistant nuclear fraction.

Conclusions:

  • RBN2397 is a potent PARP7 inhibitor with nanomolar efficacy.
  • RBN2397 inhibits prostate cancer cell growth through mechanisms distinct from IFN signaling.
  • PARP7 is a potential therapeutic target in advanced prostate cancer, including AR-negative and neuroendocrine subtypes.